PDS Biotechnology (PDSB)
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The co...
- Open
- 0.2185
- High
- 0.2221
- Low
- 0.2073
- Prev. Close
- 0.2185
- Volume
- 697.32K
- Turnover
- 148.00K
- Avg Price
- 0.2122
- Bid/Ask Ratio
- --
- Amplitude
- 6.77%
- 52wk High
- 1.5500
- Volume Ratio
- 2.85
- Turnover Ratio
- 1.35%
PDS Biotechnology Analyst Rating
View moreForecast & Rating
Aug 13, 2026Price forecast
$5.752552.21%
Forecast & RatingStrong buy
3analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · Aug 19 at 05:11 AM
Marginalized Assets in a Shifting Global Landscape: 10 Micro-Cap Stocks Testing the Macro Crosswinds
- Tip Ranks · Aug 14 at 07:28 AM
PDS Biotechnology Shareholders Approve Expanded Authorized Stock
- PUBT · Aug 14 at 07:03 AM
PDS Biotech holds annual shareholder meeting, quorum reached
- Price Alert · Aug 12 at 04:58 AM
Popular pre-market trades in the US stock market: PDS Biotechnology pre-market up 5.14%; Coherent Corp. pre-market up 5.09%
- StockTitan · Aug 10 at 11:25 PM
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101 | PDSB Stock News
- benzinga_article · Aug 11 at 12:06 PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
